Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|November 1, 2019

BioPharm International

  • BioPharm International-11-01-2019
  • Volume 32
  • Issue 11

Zippered Lab Coat

Kimberly-Clark Professional introduced the Kimtech A8 Zippered Lab Coat for liquid and particle protection for ISO 7 and 8 or higher cleanroom environments.

Kimberly-Clark Professional introduced the Kimtech A8 Zippered Lab Coat for liquid and particle protection for ISO 7 and 8 or higher cleanroom environments.

In response to customer requests for a more secure closure, the company equipped the new lab coat with a nylon zipper and no-pocket design, rather than the typical snap design, which runs the risk of contamination to people and processes because of gaps between the closures and the possibility of the snaps falling off, according to a company press release.

The lab coat is available in sizes small to 6XL with anti-static three-layer spunbond meltblown spunbond fabric, a mandarin collar for added protection, and soft knit cuffs. It can also be recycled through The RightCycle Program, a recycling program for non-hazardous lab, cleanroom, and industrial waste.

Kimberly-Clark Professional
 

 


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.